BHCM
CCCC icon

Brevan Howard Capital Management’s C4 Therapeutics CCCC Stock Holding History

Brevan Howard Capital Management’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$244K Buy
+92,647
New +$218K ﹤0.01% 1779
2024
Q3 		– Sell
-33,511
Closed -$155K – 1165
2024
Q2 		$155K Buy
33,511
+17,985
+116% +$107K ﹤0.01% 929
2024
Q1 		$127K Buy
+15,526
New +$120K ﹤0.01% 865

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Brevan Howard Capital Management's CCCC Position: Q1 2026 in Review

Brevan Howard Capital Management opened a new position in C4 Therapeutics (CCCC) in Q1 2026: 92,647 shares worth $244K. The stake represents ﹤0.01% of the portfolio and ranks #1779 among its holdings. This is a return to the name: Brevan Howard Capital Management previously reported a position in CCCC as recently as Q2 2024.

Brevan Howard Capital Management first reported a position in CCCC in Q1 2024 and has held it in 3 quarters since. 123 funds tracked by Wall St. Rank hold CCCC as of Q1 2026.

  • Brevan Howard Capital Management held 92,647 shares of C4 Therapeutics worth $244K as of Q1 2026.
  • C4 Therapeutics was a new Brevan Howard Capital Management position in Q1 2026.
  • C4 Therapeutics made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q1 2026, its #1779 holding.
  • Brevan Howard Capital Management first reported a position in C4 Therapeutics in Q1 2024 and has held it in 3 quarters since.
  • 123 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.